In the News | VenatoRx Pharmaceuticals

November 11, 2023

Contagion Live

Melinta Therapeutics Partnering with Venatorx Pharmaceuticals on Commercializing Antibiotic

Ahead of its potential approval, the company announced this week it was partnering with Parsippany, NJ-based Melinta Therapeutics in a licensing agreement to commercialize cefepime-taniborbactam.

September 1, 2023

LifeSciencesPA

Being a Life Sciences Leader Podcast

Chris Burns, PhD, President & CEO of Venatorx, joins the podcast and discusses the importance of having confidence in life and leadership. Chris describes his personal journey fighting against external hurdles, the affect psychology has on all aspects of business and his passion for bridging the intersection of science and business.

October 27, 2022

Contagion Live

Cefepime-Taniborbactam Beats Meropenem for Treating cUTI in Phase 3 Trial

Venatorx Pharmaceuticals announced successful phase 3 trial results for cefepime-taniborbactam, its investigational antibiotic aimed at treating complicated urinary tract infections.

May 24, 2022

The Hill

Antibiotic Resistance: A Looming Public Health Crisis

What threats do antibiotic-resistant superbugs pose for the future? What is being done to develop new antibiotics and bring life-saving drugs to market? And how can policymakers stimulate innovative drug developments to keep pace with evolving diseases?

April 4, 2022

STAT News

Pharma’s ambitious new antibiotic venture fund makes its first investments

One year after its splashy launch, the AMR Action Fund has made its first investments in a pair of fledgling biotech companies, a key step toward its goal of generating badly needed medicines to combat antibiotic resistance.

April 4, 2022

PharmaPhorum

Pharma-backed antibiotic fund makes first investments

AMR Action Fund said this morning that the first two beneficiaries are Adaptive Phage Therapeutics (APT) and Venatorx Pharmaceuticals, two biotechs that according to AMR Action Fund chief executive Henry Skinner “are poised to change the treatment landscape for drug-resistant infections.”

April 4, 2022

Reuters

Pharma industry-backed fund invests in two biotech companies to treat ‘superbugs’

A $1 billion fund backed by over 20 drugmakers made its first set of investments on Monday in two biotechnology startups to help struggling antibiotic makers tackle the threat of antibiotic-resistant bacteria.

April 4, 2022

Wall Street Journal

Antibiotics Venture Fund Makes Its First Two Investments

A fund that plans to invest $1 billion in antibiotics companies has made its first two deals, backing startups aiming to tackle AMR in different ways. AMR Action Fund launched in 2020 to finance smaller biotechnology companies with antimicrobial drugs in clinical trials, bridging what it says is a funding gap between early research and regulatory approval.

April 4, 2022

Bloomberg

Pharma-Backed Fund Makes First Investments in Superbug Fight

A $1 billion fund backed by some of the world’s biggest drugmakers has made its first two investments in a bid to spur the development of new antibiotics and counter the rising threat of superbugs.

April 4, 2022

Endpoint News

AMR Action Fund looks to tackle antimicrobial resistance with first two investments — but does the money arrive too late?

The AMR Action Fund has made its first two investments in the hopes of addressing the looming threat of antimicrobial resistance.

April 4, 2022

FinSMEs

Venatorx Pharmaceuticals Raises Series C Financing

Venatorx Pharmaceuticals sold shares of its Series C Preferred Stock in a financing of undisclosed amount. Proceeds from the financing will be used to support the company as it advances its novel antibacterial portfolio through the drug development process.

April 4, 2022

CIDRAP

AMR Action Fund announces its first investments

The two companies represent different approaches to combating antimicrobial resistance (AMR). One is a more traditional antibiotic approach, while the other actually predates antibiotics.

April 4, 2022

Healio | Infectious Disease News

$1 billion fund seeking new antibiotics targets phages with first investments

A $1 billion public-private partnership seeking new antibiotics announced its first investments. The AMR Action Fund said it has invested in Adaptive Phage Therapeutics and Venatorx Pharmaceuticals.

April 4, 2022

FierceBiotech

Big Pharma-backed $1B AMR Action Fund picks 1st antimicrobial biotech investments

The AMR Action Fund, backed by Big Pharmas such as Pfizer, Eli Lilly, Bayer and more, has selected the first beneficiaries of its $1 billion fund to address drug-resistant bacterial infections: Adaptive Phage Therapeutics and Venatorx Pharmaceuticals.

March 14, 2022

Medical Dialogues

Cefepime and Taniborbactam Combo Better Than Meropenem for Complicated UTI

Venatorx Pharmaceuticals today announced positive results from its pivotal Phase 3 study evaluating cefepime-taniborbactam, an investigational new drug, as a potential treatment for adult patients with complicated urinary tract infections, including acute pyelonephritis.

March 14, 2022

FDA News

Venatorx’s Combination Antibiotic Will Head to FDA

Armed with positive phase 3 data, Venatorx Pharmaceuticals will ask regulators to approve its investigational combination antibiotic, cefepime-taniborbactam, as a treatment for complicated urinary tract infections (cUTI) in adults.

March 12, 2022

AMR Insights

Venatorx Pharmaceuticals Announces Positive Results for Phase 3 Clinical Trial (CERTAIN-1) of Cefepime-Taniborbactam for Treatment of cUTI

Venatorx Pharmaceuticals today announced positive results from its pivotal Phase 3 study evaluating cefepime-taniborbactam, an investigational new drug, as a potential treatment for adult patients with complicated urinary tract infections (cUTI), including acute pyelonephritis.

March 11, 2022

pharmaphorum

Venatorx plans new antibiotic filing after phase 3 readout

Venatorx Pharmaceuticals has moved a step closer to what has unfortunately become a rare event in pharma – the filing of a new antibiotic designed to tackle the increasing pressing problem of antimicrobial resistance.

March 10, 2022

Philadelphia Business Journal

Venatorx reports positive clinical study results for its experimental antibiotic

A Chester County pharmaceutical company on Thursday announced positive results for its lead new drug candidate, an antibiotic under development to treat complicated urinary tract infections.

March 10, 2022

ContagionLive

Venatorx Pharmaceuticals Reports Positive Results for its Investigational Antibiotic for cUTI

Complicated Urinary Tract Infections can be very challenging for clinicians to treat. These UTI do not respond to traditional, first-line therapies, and due to the nature of these bacterial infections, and patients' frequent underlying health conditions, they can be more susceptible to complications including sepsis.